Archives of Pharmacal Research

, Volume 33, Issue 11, pp 1699–1701 | Cite as

This month in APR



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akiyama, Y., Maruyama, K., Nara, N., Hojo, T., Cheng, J. Y., Mori, T., Wiltrout, R. H., and Yamaguchi, K., Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters. Cancer Lett., 184, 37–47 (2002).CrossRefPubMedGoogle Scholar
  2. Banchereau, J. and Steinman, R. M., Dendritic cells and the control of immunity. Nature, 392, 245–252 (1998).CrossRefPubMedGoogle Scholar
  3. Blattman, J. N. and Greenberg, P. D., Cancer immunotherapy: a treatment for the masses. Science, 305, 200–205 (2004).CrossRefPubMedGoogle Scholar
  4. Bukowski, R. M., Sharfman, W., Murthy, S., Rayman, P., Tubbs, R., Alexander, J., Budd, G. T., Sergi, J. S., Bauer, L., Gibson, V., Stanley, J., Boyett, J., Pontes, E., and Finke, J., Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res., 51, 4199–4205 (1991).PubMedGoogle Scholar
  5. Fernandez, M. A., Puttur, F. K., Wang, Y. M., Howden, W., Alexander, S. I., and Jones, C. A., T regulatory cells contribute to the attenuated primary CD8+ and CD4+ T cell responses to herpes simplex virus type 2 in neonatal mice. J. Immunol., 180, 1556–1564 (2008).PubMedGoogle Scholar
  6. Fong, L. and Engleman, E. G., Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol., 18, 245–273 (2000).CrossRefPubMedGoogle Scholar
  7. Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., and Yee, C., Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med., 358, 2698–2703 (2008).CrossRefPubMedGoogle Scholar
  8. Kim, Y. J., Lim, J., Kang, J. S., Kim, H. M., Lee, H. K., Ryu, H. S., Kim, J. Y., Hong, J. T., Kim, Y., and Han, S.-B., Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch. Pharm. Res., 33, 1789–1795 (2010).Google Scholar
  9. Lee, K., Min, H. J., Jang, E. J., Hong, J. H., and Hwang, E. S., In vivo tumor suppression activity by T cell-specific Tbet restoration. Int. J. Cancer, 127, 2129–2137 (2010).CrossRefPubMedGoogle Scholar
  10. Lysaght, J., Jarnicki, A. G., and Mills, K. H., Reciprocal effects of Th1 and Treg cell inducing pathogen-associated immunomodulatory molecules on anti-tumor immunity. Cancer Immunol. Immunother., 56, 1367–1379 (2007).CrossRefPubMedGoogle Scholar
  11. Nishikawa, H., Tsuji, T., Jager, E., Briones, G., Ritter, G., Old, L. J., Galan, J. E., Shiku, H., and Gnjatic, S., Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood, 111, 1404–1412 (2008).CrossRefPubMedGoogle Scholar
  12. Nishikawa, H. and Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer, 127, 759–767 (2010).PubMedGoogle Scholar
  13. Prestwich, R., Vile, R., and Melcher, A., Cancer immunotherapy. N. Engl. J. Med., 359, 1072; author reply 1073 (2008).CrossRefPubMedGoogle Scholar
  14. Rosenberg, S. A., Dudley, M. E., and Restifo, N. P., Cancer immunotherapy. N. Engl. J. Med., 359, 1072 (2008a).CrossRefPubMedGoogle Scholar
  15. Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., and Dudley, M. E., Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer, 8, 299–308 (2008b).CrossRefPubMedGoogle Scholar
  16. Schreiber, T. H., Deyev, V. V., Rosenblatt, J. D., and Podack, E. R., Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res., 69, 2026–2033 (2009).CrossRefPubMedGoogle Scholar
  17. van der Burg, S. H., Piersma, S. J., de Jong, A., van der Hulst, J. M., Kwappenberg, K. M., van den Hende, M., Welters, M. J., Van Rood, J. J., Fleuren, G. J., Melief, C. J., Kenter, G. G., and Offringa, R., Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc. Natl. Acad. Sci. U. S. A., 104, 12087–12092 (2007).CrossRefPubMedGoogle Scholar
  18. Vikman, S., Sommaggio, R., De La Torre, M., Oberg, K., Essand, M., Giandomenico, V., Loskog, A., and Totterman, T. H., Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue. Acta Oncol., 48, 391–400 (2009).CrossRefPubMedGoogle Scholar
  19. Woo, E. Y., Chu, C. S., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., and June, C. H., Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and latestage ovarian cancer. Cancer Res., 61, 4766–4772 (2001).PubMedGoogle Scholar
  20. Xu, L., Xu, W., Jiang, Z., Zhang, F., Chu, Y., and Xiong, S., Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy. Cancer Biol. Ther., 8, 66–72 (2009).PubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2010

Authors and Affiliations

  1. 1.College of Pharmacy and Division of Life and Pharmaceutical SciencesEwha Womans UniversitySeoulKorea

Personalised recommendations